Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

192.87 -0.58 (-0.30%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
74 75 Next >
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment. 
Via The Motley Fool
Biotech And Healthcare Stocks Lagging
Healthcare is a laggard with XLV down YTD but UNH is still a core position. 
Via Talk Markets
RegenXbio's Potential Blockbuster: Analyst is Bullish On Stock Citing Potential Gains From AAV Gene Therapies Resurgence
Baird has initiated coverage on RegenXbio Inc (NASDAQ: RGNX) with an Outperform rating and a  
Via Benzinga
Ready for a Rebound: 7 Blue-Chips Set to Regain Their Market Mojo
Although blue-chip stocks to buy have a reputation for being slow and lumbering, these discounted ideas could swing higher. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
This Foreboding Sign Looms Over AbbVie's Chart
Via Benzinga
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
AbbVie Unusual Options Activity
Via Benzinga
Why Is AbbVie Stock Trading Down Today?
AbbVie Inc. (NYSE: ABBV) shares are trading lower Thursday after Coherus BioSciences Inc. 
Via Benzinga
Vanguard’s High Dividend Yield (VYM) ETFs Q2 Dividend – Growth
This ETF has been around for almost 20 years and boasts a very low 0.06% expense ratio. 
Via Talk Markets
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
An immunology drug of the Swiss pharmaceutical giant was approved for yet another indication in the European Union. 
Via The Motley Fool
Unlock the Potential of These 7 Cash-Flow Machines
Here are seven high cash flow stocks that provide investors with both growth and value under any economic conditions. 
Via InvestorPlace
This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy?
Coherus' biosimilar to Humira could catapult the company to success. 
Via The Motley Fool
AbbVie Touts Promising Results For Risankizumab For Ulcerative Colitis Maintenance
AbbVie Inc (NYSE: ABBV) announced top-line results from the COMMAND Phase 3 maintenance study, showing risankizumab (Skyrizi) achieved the primary endpoint of clinical remission at week 52, as well as... 
Via Benzinga
AbbVie vs Coherus: Dispute Emerges over Upcoming Launch of Low-Cost Biosimilar, Yusimry
AbbVie Inc (NYSE: ABBV) has challenged Coherus BioSciences Inc (NASDAQ: CHRS), alleging Coherus breached its settlement and license agreement after it announced its plans to launch Yusimry, a... 
Via Benzinga
AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent
BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics  
Via Benzinga
AbbVie, Deere And A Major Chipmaker Set To Win In AI: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said AbbVie Inc. 
Via Benzinga
Tuesday Talk: Not Clear Yet
It is not yet clear if the Fed will raise rates by a quarter point or engage in a rate hike pause, at tomorrow's FOMC meeting. The current reading on FedWatch is 79.2% pro-pause. 
Via Talk Markets
High-Yield And Attractively Valued Dividend Stocks
A look at some of the high dividend yields that are available currently, which provide both a solid income and appreciation potential. 
Via Talk Markets
Negotiation or Coercion? Big Pharma and US Chamber of Commerce Tackle Government on Drug Prices
The U.S. Chamber of Commerce has filed a lawsuit against the federal government, challenging a recent law that grants Medicare the authority to negotiate drug prices with pharmaceutical companies. 
Via Benzinga
XPeng's New EV Is a Hit, but This Biotech Stock Is Leaving It in the Dust
Find out more about two big winners Monday morning. 
Via The Motley Fool
7 Top Blue-Chip Stocks to Buy in June 2023
Investors who are looking to hold stocks through the summer should be looking for the best blue-chip stocks to buy. 
Via InvestorPlace
Better Long-Term Buy: AbbVie or Novo Nordisk?
It's important to factor in a pharmaceutical company's pipeline depth. 
Via The Motley Fool
Is AbbVie or Amgen the Better Bargain Buy Right Now?
These elite drugmakers are both working through a number of headwinds. 
Via The Motley Fool
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It 'Extortion'
Merck & Co Inc (NYSE: MRK) has reportedly filed a lawsuit against the U.S. government to halt implementing the Medicare drug price negotiation program outlined in the Inflation Reduction Act (IRA).  
Via Benzinga
$300 a Month in These 3 Stocks Could Make You a Millionaire by Retirement
These three stocks have all produced market-beating returns for shareholders in recent years. 
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
7 Best Dividend Stocks to Buy Now in June 2023
These top dividend stocks are attractive at these levels and lower, and they add excellent diversity to a long-term investing portfolio. 
Via The Motley Fool
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed'
One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug... 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.